New drug combo targets tough T-Cell lymphoma
NCT ID NCT07388563
First seen Feb 05, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This early-phase trial tests whether combining two existing drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The main goals are to find the safest dose and see how well the combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.